Von Seebach competitive analysis

Latest publications and patents of Von Seebach New

Explore the latest publications and patents granted to Von Seebach, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Von Seebach against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Dosage Regimen For A S1P Receptor AgonistNOVARTISMar 3, 2021
Dosage Regimen For A S1P Receptor AgonistNOVARTISAug 18, 2020
Apixaban FormulationsBRISTOL MYERS SQUIBB IRELANDAug 6, 2020

Latest PTAB cases involving Von Seebach

Discover the latest PTAB cases involving Von Seebach, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Von Seebach with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
VON SEEBACH3 - - - Highly Aggressive
BRISTOL MYERS SQUIBB IRELAND - 42 - - Non-Active
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 42 - - Non-Active
NOVARTIS6406 - 21Defensive